Recently I am researching about POLY(PROPYLENE SULFIDE) NANOPARTICLES; DENDRITIC CELLS; ADAPTIVE IMMUNITY; CELLULAR-IMMUNITY; VIVO; TRANSPORT; PEPTIDES; ACTIVATION; MOLECULES; THERAPY, Saw an article supported by the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) – USA [R01CA247484, R01CA207619, S10OD016264, T32EB021962, T32GM008433]; National Science FoundationNational Science Foundation (NSF) [CHE 1011796]; Parker H. Petit Institute for Bioengineering and Bioscience at the Georgia Institute of Technology; Georgia CORE/It’s the Journey; American Heart AssociationAmerican Heart Association; National Science Foundation Graduate Research Fellowship ProgramNational Science Foundation (NSF). HPLC of Formula: C4H14Cl2N2S2. Published in NATURE PUBLISHING GROUP in LONDON ,Authors: Schudel, A; Chapman, AP; Yau, MK; Higginson, CJ; Francis, DM; Manspeaker, MP; Avecilla, ARC; Rohner, NA; Finn, MG; Thomas, SN. The CAS is 56-17-7. Through research, I have a further understanding and discovery of 2,2′-Disulfanediyldiethanamine dihydrochloride
Therapeutic delivery selectively to lymph nodes has the potential to address a variety of unmet clinical needs. However, owing to the unique structure of the lymphatics and the size-restrictive nature of the lymph node reticular network, delivering cargo to specific cells in the lymph node cortex and paracortex is difficult. Here, we describe a delivery system to overcome lymphatic and intra-lymph node transport barriers by combining nanoparticles that are rapidly conveyed to draining lymph nodes after administration in peripheral tissues with programmable degradable linkers. This platform enables the controlled release of intra-lymph-mobile small-molecular cargo, which can reach vastly more immune cells throughout the lymph node than either the particles or free compounds alone. The release rate can be programmed, allowing access to different lymph node structures and therefore specific lymphocyte subpopulations. We are thus able to alter the subtypes of drugged lymph node cells to improve immunotherapeutic effects. Nanoparticles that access lymphatic vessels and are functionalized with degradable linkers, whose half-lives can be programmed, enable the controlled release of therapeutic cargo in different regions of the lymph nodes, allowing the targeting of otherwise difficult-to-reach lymphocyte subpopulations.
HPLC of Formula: C4H14Cl2N2S2. Welcome to talk about 56-17-7, If you have any questions, you can contact Schudel, A; Chapman, AP; Yau, MK; Higginson, CJ; Francis, DM; Manspeaker, MP; Avecilla, ARC; Rohner, NA; Finn, MG; Thomas, SN or send Email.
Reference:
Thiazine – an overview | ScienceDirect Topics,
,Thiazine | C4H5NS – PubChem